Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

The data show that a regimen based on Trodelvy and PD-1 inhibitor Keytruda (pembrolizumab) was better than Keytruda plus ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

March was a light month across the board for hires news, but the digital and supplier sectors in biopharma saw a spat of ...

The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China, and Japan gave a green light to ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

UK-based life science investor Syncona has launched a new company – Slingshot Therapeutics – with a mission to find promising projects in academia and translate them into full-blown ...

Researchers from the Wellcome Sanger Institute and partners have carried out a comprehensive analysis of cancer cells, identifying 370 ‘priority’ targets that could be used to develop new drug ...

The healthcare industry is on the cusp of change, with artificial intelligence (AI) and predictive analytics paving the way for unprecedented advancements in patient care and operational efficiency.

Intercept Pharma's hopes of getting its non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA) in the US may have taken another dive, after it flunked a phase 3 trial. Shares in the ...

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion.

As the news that NHS England is to be dismantled sinks in, the British Medical Association (BMA) and other bodies have weighed in on the decision. According to Prof Phil Banfield, chair of the BMA ...